DrugsNews.net

Drugs Xagena

Acute myeloid leukaemia ( AML ) is an aggressive and devastating blood cancer. It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World. The current ...


The FDA ( Food and Drug Administration ) has approved Velcade ( Bortezomib ) for the retreatment of adult patients with multiple myeloma who had previously responded to Bortezomib therapy and relapsed ...


The FDA ( Food and Drug Administration ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Promacta ( Eltrombopag; Europe: Revolade ) in patients with severe aplastic ...


The European Commission ( EU ) has approved the use of Avastin ( Bevacizumab ) in combination with Paclitaxel, Topotecan, or Pegylated liposomal doxorubicin chemotherapy as a treatment for women with ...


The FDA ( Food and Drug Administration ) has granted priority review designation for Ivabradine for the treatment of chronic heart failure ( HF ). Ivabradine is an oral drug that inhibits the If cu ...


The Food and Drug Administration ( FDA ) has approved a supplement to expand the indication for Lumizyme ( Alglucosidase alfa ). Lumizyme manufactured at the 4000L scale is now indicated for all Pompe ...


The FDA ( Food and Drug Administration ) has approved Cerdelga ( Eliglustat ) for the long-term treatment of adult patients with the type 1 form of Gaucher disease, a rare genetic disorder. Gaucher d ...


The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...


Paracetamol ( Acetaminophen ) poisoning is common worldwide. It is treated with intravenous Acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to ...


A retrospective cohort study has evaluated the effect of anesthesia type on the risk of in-hospital mortality among adults undergoing hip fracture surgery in the United States. Participants were 73 ...


The objective of a study was to describe rates and risk factors for prolonged postoperative use of opioids in patients who had not previously used opioids and undergoing major elective surgery. The ...


Eliquis ( Apixaban ) is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Apixaban decreases thrombin generation and blood clot formation. Eliquis is ap ...


Stivarga ( Regorafenib ) has been approved by the European Commission ( EC ) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ( GIST ) who progressed ...


Eylea ( Aflibercept ) injection has been approved by the European Commission for the treatment of visual impairment due to diabetic macular edema ( DME ). Diabetetic macular edema is the leading caus ...


Kalydeco ( Ivacaftor ) is the first medicine to treat the underlying cause of cystic fibrosis in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, Ivacaftor is an oral me ...


Hydroxychloroquine ( Plaquenil ) is indicated for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and malaria ( acute attacks and suppressive treatment ). Hypoglyce ...


Six Canadian cases of aortic thrombosis have been reported in cancer patients after initiation of treatment with Cisplatin, in addition to 15 published international cases. In many of these patients, ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive scientific opinion in accordance with Article 58 of Regulation ( EC ) No 726/2004, for the medicinal product Hemopros ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Nerventra, intended for th ...


The European Medicines Agency ( EMA ), the Committee for Medicinal Products for Human Use ( CHMP ), and the European Commission ( EC ) have granted market authorization renewal for Angiox ( Bivalirudi ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati